EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 24 (2017) Parasite, 24 (2017) 5 References
Open Access
Issue
Parasite
Volume 24, 2017
Article Number 5
Number of page(s) 9
DOI https://doi.org/10.1051/parasite/2017004
Published online 01 February 2017
  1. Bessieres MH, Swierczynski B, Cassaing S, Miedouge M, Olle P, Seguela JP, Pipy B. 1997. Role of IFN-gamma, TNF-alpha, IL4 and IL10 in the regulation of experimental Toxoplasma gondii infection. Journal of Eukaryotic Microbiology, 44(6), 87S. [CrossRef] [Google Scholar]
  2. Buxton D. 1993. Toxoplasmosis: the first commercial vaccine. Parasitology Today, 9(9), 335–337. [CrossRef] [Google Scholar]
  3. Chuang SC, Ko JC, Chen CP, Du JT, Yang CD. 2013. Encapsulation of chimeric protein rSAG1/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against Toxoplasma gondii in mice. Experimental Parasitology, 134(4), 430–437. [CrossRef] [PubMed] [Google Scholar]
  4. Chuang SC, Ko JC, Chen CP, Du JT, Yang CD. 2013. Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasites & Vectors, 6, 34. [CrossRef] [PubMed] [Google Scholar]
  5. Chuang SC, Yang CD. 2014. Sustained release of recombinant surface antigen 2 (rSAG2) from poly(lactide-co-glycolide) microparticles extends protective cell-mediated immunity against Toxoplasma gondii in mice. Parasitology, 141(12), 1657–1666. [CrossRef] [Google Scholar]
  6. Contini C. 2008. Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient. Parassitologia, 50(1–2), 45–50. [PubMed] [Google Scholar]
  7. Delhaes L, Ajzenberg D, Sicot B, Bourgeot P, Darde ML, Dei-Cas E, Houfflin-Debarge V. 2010. Severe congenital toxoplasmosis due to a Toxoplasma gondii strain with an atypical genotype: case report and review. Prenatal Diagnosis, 30(9), 902–905. [CrossRef] [PubMed] [Google Scholar]
  8. Dubey JP. 2008. The history of Toxoplasma gondii – the first 100 years. Journal of Eukaryotic Microbiology, 55(6), 467–475. [CrossRef] [Google Scholar]
  9. Gupta RK, Singh M, O’Hagan DT. 1998. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Advanced Drug Delivery Reviews, 32(3), 225–246. [CrossRef] [PubMed] [Google Scholar]
  10. Heegaard PM, Dedieu L, Johnson N, Le Potier MF, Mockey M, Mutinelli F, Vahlenkamp T, Vascellari M, Sorensen NS. 2011. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Archives of Virology, 156(2), 183–202. [CrossRef] [PubMed] [Google Scholar]
  11. Hill D, Dubey JP. 2002. Toxoplasma gondii: transmission, diagnosis and prevention. Clinical Microbiology and Infection, 8(10), 634–640. [CrossRef] [Google Scholar]
  12. Jain S, O’Hagan DT, Singh M. 2011. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Review of Vaccines, 10(12), 1731–1742. [CrossRef] [PubMed] [Google Scholar]
  13. Johnson LL, Sayles PC. 2002. Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice. Infection and Immunity, 70(1), 185–191. [CrossRef] [PubMed] [Google Scholar]
  14. Jongert E, Roberts CW, Gargano N, Forster-Waldl E, Petersen E. 2009. Vaccines against Toxoplasma gondii: challenges and opportunities. Memórias do Instituto Oswaldo Cruz, 104(2), 252–266. [CrossRef] [Google Scholar]
  15. Jongert E, Lemiere A, Van Ginderachter J, De Craeye S, Huygen K, D’Souza S. 2010. Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Vaccine, 28(13), 2556–2564. [CrossRef] [PubMed] [Google Scholar]
  16. Kang H, Remington JS, Suzuki Y. 2000. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. Journal of Immunology, 164(5), 2629–2634. [CrossRef] [Google Scholar]
  17. Kavanagh OV, Earley B, Murray M, Foster CJ, Adair BM. 2003. Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(DL-lactide-co-glycolide) microspheres. Vaccine, 21(27–30), 4472–4480. [CrossRef] [PubMed] [Google Scholar]
  18. Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP. 2016. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 126(1), 318–334. [CrossRef] [Google Scholar]
  19. Liu Q, Singla LD, Zhou H. 2012. Vaccines against Toxoplasma gondii: status, challenges and future directions. Human Vaccines & Immunotherapeutics, 8(9), 1305–1308. [CrossRef] [PubMed] [Google Scholar]
  20. Mammari N, Vignoles P, Halabi MA, Dardé ML, Courtioux B. 2015. Interferon gamma effect on immune mediator production in human nerve cells infected by two strains of Toxoplasma gondii. Parasite, 22, 39. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Overbergh L, Valckx D, Waer M, Mathieu C. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine, 11(4), 305–312. [CrossRef] [Google Scholar]
  22. Raman C, Berkland C, Kim K, Pack DW. 2005. Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. Journal of Controlled Release, 103(1), 149–158. [CrossRef] [Google Scholar]
  23. Robert-Gangneux F, Darde ML. 2012. Epidemiology of and diagnostic strategies for toxoplasmosis. Clinical Microbiology Reviews, 25(2), 264–296. [CrossRef] [PubMed] [Google Scholar]
  24. Sivakumar SM, Safhi MM, Kannadasan M, Sukumaran N. 2011. Vaccine adjuvants – current status and prospects on controlled release adjuvancity. Saudi Pharmaceutical Journal, 19(4), 197–206. [CrossRef] [Google Scholar]
  25. Sousa S, Canada N, Correia da Costa JM, Darde ML. 2010. Serotyping of naturally Toxoplasma gondii infected meat-producing animals. Veterinary Parasitology, 169(1–2), 24–28. [CrossRef] [PubMed] [Google Scholar]
  26. Sturesson C, Carlfors J. 2000. Incorporation of protein in PLG-microspheres with retention of bioactivity. Journal of Controlled Release, 67(2–3), 171–178. [CrossRef] [Google Scholar]
  27. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science, 240(4851), 516–518. [CrossRef] [PubMed] [Google Scholar]
  28. Uchida M, Natsume H, Kishino T, Seki T, Ogihara M, Juni K, Kimura M, Morimoto Y. 2006. Immunization by particle bombardment of antigen-loaded poly-(DL-lactide-co-glycolide) microspheres in mice. Vaccine, 24(12), 2120–2130. [CrossRef] [PubMed] [Google Scholar]
  29. Verma R, Khanna P. 2013. Development of Toxoplasma gondii vaccine: a global challenge. Human Vaccines & Immunotherapeutics, 9(2), 291–293. [CrossRef] [PubMed] [Google Scholar]
  30. Weiss LM, Dubey JP. 2009. Toxoplasmosis: a history of clinical observations. International Journal for Parasitology, 39(8), 895–901. [CrossRef] [PubMed] [Google Scholar]
  31. Yang CD, Chang GN, Chao D. 2004. Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2. Parasitology Research, 92(1), 58–64. [CrossRef] [PubMed] [Google Scholar]
  32. Ye M, Kim S, Park K. 2010. Issues in long-term protein delivery using biodegradable microparticles. Journal of Controlled Release, 146(2), 241–260. [CrossRef] [Google Scholar]
  33. Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ. 2013. Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Review of Vaccines, 12(11), 1287–1299. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.